Spectral MD
Title
Wound Assessment Using Spectral Imaging (WAUSI)
Engagement Type
Company Fully Funded
Industry Partner
Spectral MD, Inc., a wholly owned subsidiary of Spectral AI, Inc. (Nasdaq: MDAI), is a US company specialising in imaging technology that provides clinicians with faster and more accurate treatment decisions in wound care. The company’s DeepView wound imaging system uses AI and multispectral imaging to provide clinicians with immediate wound healing prediction information that is not visible to the human eye.
Challenges
Diabetic foot ulcers affect millions of patients globally each year and have the potential to require multiple treatments, develop gangrene and lead to amputation. They also come at an extreme costs and burden to the healthcare system. Early and accurate diagnosis is key to improving healing rates and overall outcomes and as a result dramatically enhancing patient quality of life.
Spectral MD engaged in a collaborative research project with the School of Nursing and Midwifery at RCSI. The project helped identify the potential use of Spectral’s DeepView technology in the diagnosis and add to the database of the AI prediction of diabetic foot ulcers reducing the area of closure by 50% in four weeks.
RCSI Value Added
The RCSI Skin Wounds and Trauma (SWaT) Research Centre is leading cutting-edge research in the field of wound healing and tissue repair, with a specific emphasis on pressure ulcer prevention and management. Specialising in the evaluation and regulated clinical investigations of novel medical devices, the SWaT Research Centre is a hub for industry partners seeking to evolve – and bring to market – wound care prevention and treatment devices.
Strong partnerships with clinical and academic institutions, close relationships with patients and patient advocacy groups, and the core of expertise that is the SWaT Network, make the Centre the ideal partner for companies working on outcome-focused healthcare, and the translation of scientific evidence into contemporary clinical decision-making and practice.
The project team for this collaboration included Prof. Declan Patton (PI), Prof. Zena Moore (Co-PI), Chief Clinical Investigator Prof. John McDermott and Clinical Sub Investigator Prof. Seamus Sreenan, both from Connolly Hospital.
“We are delighted to partner with such a world-renowned institution. Working in partnership with RCSI’s Skin Wounds and Trauma Research Centre and Office of Research and Innovation, we have successfully navigated the development of this relationship that harnesses our collective expertise.”
–Wensheng Fan, CEO, Spectral MD.